Eisai announces agreement to set up new gastrointestinal speciality company
March 30, 2016Manufacturing and Production, Research and Development, Sales and Marketing Ajinomoto, Eisai, absorption, acquisition, ea pharma, gastrointestinal, merger, speciality
Eisai (TYO: 4523) and Ajinomoto Co. (TYO: 2802) have announced an agreement to establish a new gastrointestinal speciality pharmaceutical company, …
FDA says positives outweigh risks on Acadia’s Parkinson’s psychosis drug
March 30, 2016Research and Development, Sales and Marketing FDA, Parkinson's, Parkinsons, acadia, nuplazid, pimavanserin, psychosis
Acadia Pharmaceuticals (NASDAQ: ACAD) has announced a positive result from the US Food and Drug Administration (FDA) concerning Nuplazid (pimavanserin) …
Biosimilars could save healthcare systems $100bn by 2020
March 30, 2016Research and Development, Sales and Marketing biosimilars
The growth of the market for biosimilar drugs has the potential to save EU and US healthcare systems up to …
Lupin drops on FDA observations; company reassures of no disruption at facility
March 29, 2016Business Services, Manufacturing and Production, Sales and Marketing Lupin, US FDA, regulation
Shares of India’s Lupin dropped over 14% Tuesday following news the US Food and Drug Administration (FDA) has made observations …
GSK’s Nucala gets regulatory approval in Japan to treat bronchial asthma
March 29, 2016Manufacturing and Production, Research and Development GlaxoSmithKline, Japan, Nucala, US FDA, bronchial asthma
GlaxoSmithKline (LSE: GSK) on Tuesday said the Japanese regulators have approved its drug to treat bronchial asthma. The Japanese Ministry …
Valeant’s outgoing CEO subpoenaed by US congressional committee
March 29, 2016Medical Communications, Research and Development Drug pricing, Michael Pearson, US, Valeant, committee, pearson, pharma, price hikes, senate aging committee, subpoena, subpoenaed
The US Senate Aging Committee has announced the issuing of a subpoena to the outgoing CEO of Valeant Pharmaceuticals, Michael …
TREND: Rare disease, cancer drugs will drive pharma M&A’s, growth
March 29, 2016Manufacturing and Production, Research and Development, Sales and Marketing M&A, MA, Orphan Drugs, cancer drugs
Moody’s Investor Service lowered its growth outlook for the global pharma sector but maintained the mergers and acquisitions in the …
Novo Nordisk breaks ground on new $2 billion production facility in North Carolina
March 29, 2016Manufacturing and Production, Research and Development $2 billion, Clayton, Novo, Novo Nordisk, building, diabetes, nordisk, north carolina, production facility
Novo Nordisk has begun work on a new $2 billion production facility in Clayton, North Carolina, which will produce active …
US FDA issues observations for Natco Pharma’s Indian plants
March 29, 2016Manufacturing and Production, Research and Development, Sales and Marketing
Shares in India-based Natco Pharma (BOM: 524816) dropped on the Bombay Stock Exchange following news the US Food and Drug …
Sanofi names MedImmune chief head of research
March 29, 2016Sanofi has announced the appointment of Yong-Jun Liu as head of research at the French company.Liu, an immunology specialist with …
Portola Pharma stock drops on dismal Phase III trial results for blood-clot drug
March 29, 2016Manufacturing and Production, Research and Development, Sales and Marketing Portola Pharmaceuticals, blood clot drug, drug trial, phase III
Shares in Portola Pharmaceuticals (Nasdaq: PTLA) dropped after the company reported disappointing late-stage trial results for its blood clotting drug. …
FDA issues CRL for Takeda/Lundbeck’s Brintellix
March 29, 2016Manufacturing and Production, Research and Development Lundbeck, Takeda, brintellix
Takeda and Lundbeck have received a complete response letter from the US Food and Drug Administration (FDA) for the supplemental …
US govt demands records of Novartis’ educational events in kickbacks suit
March 29, 2016Business Services, Manufacturing and Production, Sales and Marketing Novartis, US government, legal, regulation
Swiss pharma major Novartis (VTX: NOVN) has said the US lawsuit has exploded with the regulators demanding information for about …
Japanese approval for AZ lung cancer drug
March 29, 2016Manufacturing and Production, Sales and Marketing AstraZeneca, Tagrisso, lung cancer
AstraZeneca’s Tagrisso (osimertinib) has been approved in Japan for the treatment of a specific form of clung cancer. Japanese regulator, …
Mylan launches generic of Valeant’s Ultram in the US
March 29, 2016Manufacturing and Production, Sales and Marketing FDA, Mylan, Valeant, abbreviate new drug application, generic, pain, tramadol, ultram
Mylan (NASDAQ, TASE: MYL) has announced the launch of its generic version of Valeant’s Ultram tablets in the US. The …
Gilead must pay MSD $200m in hep C drug patent case
March 29, 2016Manufacturing and Production, Sales and Marketing Gilead Sciences, MSD, Solvadi, harvoni
A Californian federal jury has ordered Gilead Sciences to pay MSD and Ionis $200 million for infringing on patents relating …
PTC Therapeutics to cut jobs after FDA rejects Duchenne drug
March 24, 2016Manufacturing and Production Duchenne Muscular Dystrophy, PTC Therapeutics
PTC Therapeutics has announced plans to reduce its operating expenses that will see it cut almost a fifth of its …
Phase III trial initiated for enzalutamide in treatment of prostate cancer
March 24, 2016Research and Development Astellas, Medivation, arches, clinical trial, enzalutamide, phase 3, phase III, prostate cancer
Astellas Pharma (TSE: 4503) and Medivation (NASDAQ:MDVN) have announced the initiation of the ARCHES Phase III clinical trial to evaluate …
Sun Pharma agree deal to distribute AstraZeneca type-2 diabetes drug in India
March 24, 2016Sales and Marketing AstraZeneca, India, Sun Pharma, diabetes, oxra, type 2, type-2
Sun Pharma has agreed a deal with AstraZeneca to promote and distribute their type-2 diabetes drug, dapagliflozin, in India. Marketed …
MSD teams up with Harvard to develop new leukaemia treatments
March 24, 2016Medical Communications, Research and Development AML, Harvard, MSD, leukaemia
MSD has entered a new collaboration with Harvard University aimed at developing innovative new small-molecule therapeutics for leukaemia and other …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
